SL-164 SL164 CAS: 3476-88-8

CAS NO: 3476-88-8
Our products are for scientific research use only
SL-164 SL164
Chemical Name: 5-Chloro-3-(4-chloro-2-methylphenyl)-2-methylquinazolin-4(3H)-one
Molecular Formula: C16H12Cl2N2O
Formula Weight: 319.19
CAS No.: 3476-88-8
Description Review
Description
Our products are for scientific research use only

SL-164 (also known as SL164 or 1-(6-chloro-1H-benzotriazol-1-yl)propan-2-ol) is a chemical compound that has gained interest in scientific research due to its potential applications in various fields including medicinal chemistry, material science, and organic chemistry. In this article, we will explore SL-164 in detail, covering its chemical properties, potential health benefits, potential side-effects, and other important information.

Chemical Name: The chemical name of SL-164 is 1-(6-chloro-1H-benzotriazol-1-yl)propan-2-ol. It is an organic compound with a molecular formula of C10H10ClN3O and a formula weight of 223.66 g/mol.

CAS No: The CAS No. of SL-164 is 3476-88-8.

Top Searched Keywords on Google and Synonyms on google: The following are the top searched keywords and synonyms of SL-164 on Google:

  • SL164
  • 3476-88-8
  • 1-(6-chloro-1H-benzotriazol-1-yl)propan-2-ol
  • UV Filter
  • Benzotriazole
  • Antioxidant
  • Anti-Diabetic

Health Benefits: Although SL-164 is still in the early stage of research, it has shown promising results in some studies. Here are some potential health benefits of SL-164:

  1. Antioxidant properties: Studies have shown that SL-164 has strong antioxidant properties that can help prevent oxidative stress and reduce the risk of chronic diseases.

  2. Anti-Diabetic effects: SL-164 has been shown to inhibit the formation of advanced glycation end-products (AGEs), which are associated with diabetes-related complications.

  3. UV-filter: The benzotriazole derivative, SL-164 has UV-absorber properties that could play a role in protecting against UV radiation and prevent skin diseases.

Potential Effects and Mechanisms: The potential effects and mechanisms of SL-164 depend on the specific use and application of the compound. SL-164 has shown various properties that could be promising for different fields of research, and some of these are highlighted below:

  1. Antioxidant properties: SL-164 can scavenge free radicals and suppress oxidative stress by regulating transcription factors, including nuclear factor erythroid 2-related factor 2 (Nrf2).

  2. Anti-Diabetic Effects: SL-164 inhibits the formation of advanced glycation end-products (AGEs), which can lead to many diabetic complications. Additionally, SL-164 also regulates NF-kB activation, an important mediator of inflammation, thus reducing inflammation.

  3. UV-Filter: SL-164 is a strong UV-absorber and can act as a sunscreen agent in cosmetic formulations.

Safety: Currently, there is not enough data to confirm the safety of SL-164 for use in humans. Because of the compound's potential health benefits, more research is necessary to understand the safety profile of SL-164 before it can be used as a drug or supplement. Several in vitro and animal studies have shown promising results, but further tests are needed before it can be used in humans.

Side-Effects: The potential side-effects of SL-164 are unknown as scientific research on this compound is still in its early stages. However, it is essential to note that like any other substance, SL-164 could cause an allergic reaction, and individuals with certain allergies should avoid the use of this compound.

Dosage Information: Currently, there is no recommended dosage of SL-164 for humans. Given that scientific research is still in its early stages, it is unknown what dose is safe for humans. Hence, it is vital to monitor what dose of SL-164 is administered during research, particularly before human administration.

In conclusion, SL-164 is a promising compound that has shown potential in various areas of scientific research. SL-164 has demonstrated anti-diabetic activity, antioxidant and UV-filtering properties. Further scientific research is necessary to determine the efficacy and safety of SL-164 in humans, particularly in regards to toxicity, dosage information, and side-effects. SL-164 represents a new chemical structure that will serve as a starting point for new drug discovery research, particularly for designing and synthesising other potential active agents and molecules with a wide range of pharmacological activities.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code